scholarly journals Clinical Prediction Score for Community-Onset Bloodstream Infections Caused by Extended-Spectrum Beta-Lactamase-Producing Escherichia coli and Klebsiella Species

2019 ◽  
Vol 34 (14) ◽  
Author(s):  
Moonsuk Kim ◽  
Kyoung-Ho Song ◽  
Chung-Jong Kim ◽  
Pyoeng Gyun Choe ◽  
Wan Beom Park ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Bloodstream Infections ◽  
Prediction Score ◽  
Beta Lactamase ◽  
Clinical Prediction ◽  
Klebsiella Species ◽  
Extended Spectrum Beta Lactamase ◽  
Extended Spectrum ◽  
Community Onset

scholarly journals Detection of CTX-M gene in extended spectrum beta lactamase (ESBL) producing Escherichia coli and Klebsiella species of different hospitals.

2012 ◽  
Vol 4 (2) ◽  
pp. 28-31 ◽  
Author(s):  
Nawshad Muhammad Wahidur Rahman ◽  
Afzalunnessa Binte Lutfor ◽  
Sanya Tahmina Jhora ◽  
Mahmuda Yasmin ◽  
Jalaluddin Ashraful Haq
Keyword(s):  
Escherichia Coli ◽  
Tertiary Care ◽  
Beta Lactamase ◽  
M Gene ◽  
Klebsiella Species ◽  
Extended Spectrum Beta Lactamase ◽  
Extended Spectrum ◽  
Synergy Test ◽  
Tertiary Care Hospitals ◽  
Klebsiella Spp

A total of 200, non-duplicate ESBL producing strains (171 Escherichia coli and 29 Klebsiella spp.) from three tertiary care hospitals were detected using screening test & double disc synergy test. All isolates were screened for the detection of CTX-M type Extended spectrum Beta-lactamase (ESBL) using PCR. Among them 133 (66.5%) were positive for CTX-M type ESBLs which include 114 (66.66%) E.coli and 19 (65.51%) Klebsiella spp. This is the first report of identifying CTX-M gene in ESBL producing Escherichia coli and Klebsiella species of different hospitals.DOI: http://dx.doi.org/10.3329/bjmm.v4i2.10829 

Wide dissemination of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella spp. in acute care and rehabilitation hospitals

2011 ◽  
Vol 140 (3) ◽  
pp. 528-534 ◽  
Author(s):  
A. KOHLENBERG ◽  
F. SCHWAB ◽  
H. RÜDEN
Keyword(s):  
Escherichia Coli ◽  
Control Measures ◽  
Beta Lactamase ◽  
Extended Spectrum Beta Lactamase ◽  
Extended Spectrum ◽  
The Mean ◽  
Rehabilitation Hospitals ◽  
Klebsiella Spp ◽  
Wide Dissemination ◽  
Community Onset

SUMMARYA prospective surveillance system for extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-E) and ESBL-producing Klebsiella spp. (ESBL-K) was implemented in 39 German hospitals with the aim of determining the incidence densities (IDs) of community-onset and hospital-onset cases and of identifying risk factors for high IDs of hospital-onset cases. During 2008, 2081 ESBL-E/K cases were documented. ESBL-E cases (n=1330, 63·9%) were more common than ESBL-K cases (n=751, 36·1%), but a higher proportion of ESBL-K cases (59%) than of ESBL-E cases (39·5%) were hospital-onset cases. The mean IDs were 0·54 (range 0–2·53) per 1000 patient-days for all ESBL-EK cases, 0·29 (range 0–1·81) per 1000 patient-days for community-onset ESBL-EK cases and 0·25 (range 0–1·82) per 1000 patient-days for hospital-onset ESBL-EK cases. Regression analysis showed a linear association between the IDs of community-onset and hospital-onset cases. The wide dissemination of ESBL-E and ESBL-K emphasizes the need for hospital-wide surveillance to guide control measures.

Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase–Producing Enterobacteriaceae

2015 ◽  
Vol 36 (8) ◽  
pp. 981-985 ◽  
Author(s):  
Hadas Ofer-Friedman ◽  
Coral Shefler ◽  
Sarit Sharma ◽  
Amit Tirosh ◽  
Ruthy Tal-Jasper ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Multivariate Analysis ◽  
Urinary Tract ◽  
Odds Ratio ◽  
Adjusted Odds Ratio ◽  
Bloodstream Infections ◽  
Beta Lactamase ◽  
Extended Spectrum Beta Lactamase ◽  
Efficacy Analysis ◽  
Extended Spectrum

A recent, frequently quoted study has suggested that for bloodstream infections (BSIs) due to extended-spectrum β-lactamase–producing Enterobacteriaceae (ESBL) Escherichia coli, treatment with β-lactam/β-lactamase inhibitors (BLBLIs) might be equivalent to treatment with carbapenems. However, the majority of BSIs originate from the urinary tract. A multicenter, multinational efficacy analysis was conducted from 2010 to 2012 to compare outcomes of patients with non-urinary ESBL BSIs who received a carbapenem (69 patients) vs those treated with piperacillin-tazobactam (10 patients). In multivariate analysis, therapy with piperacillin-tazobactam was associated with increased 90-day mortality (adjusted odds ratio, 7.9, P=.03). For ESBL BSIs of a non-urinary origin, carbapenems should be considered a superior treatment to BLBLIs.Infect Control Hosp Epidemiol 2015;36(8):981–985

Sign in / Sign up

Export Citation Format

Share Document